Hemcheck has received a follow up order from its French distributor
SOLNA, Sweden, Feb. 3, 2023 /PRNewswire/ -- Hemcheck has received a follow-up order from its French distributor, Eurobio Scientific, corresponding to approximately SEK 80,000. The order concerns instruments for diagnostic use.
- We have a positive trend in terms of sales, which is very positive. Several of our distributors are very active and there is clear potential in especially the larger markets. We hope and believe we will get more similar orders, says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck's goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
The following files are available for download:
HC PM Eurobio 2023 ENG
View original content:https://www.prnewswire.co.uk/news-releases/hemcheck-has-received-a-follow-up-order-from-its-french-distributor-301738478.html
Upcoming Life Sciences Events
- June 2023
- Boston: Product & Company Valuation Course
- BIO International Convention 2023
- RESI Boston
Latest company news
Sectra's year-end report 2022/2023: Historic quarter to end another successful fiscal year--higher dividend proposed
Sobi to present new data at the 2023 EHA congress
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima